Rezolute's Ersodetug Nears Key Data Readouts for Hyperinsulinism

TL;DR

**RZLT is a high-stakes bet on ersodetug's upcoming Phase 3 data, which could either skyrocket or sink the stock.**

AI Summary

Rezolute, Inc. (RZLT) is a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI). Their lead asset, ersodetug, an intravenously administered human monoclonal antibody, is being developed for congenital HI and tumor HI. The pivotal Phase 3 sunRIZE study for congenital HI completed enrollment in May 2025, with topline results anticipated in December 2025. The study enrolled over 56 participants, with an average age of 3.4 years and 95% on standard of care treatments, experiencing an average of 15 hypoglycemia events per week. For tumor HI, the upLIFT Phase 3 study was initiated in mid-2025, with topline results expected in the second half of 2026. The FDA agreed to a modified, truncated single-arm open-label study for upLIFT, requiring as few as 16 participants. Ersodetug has received multiple designations, including Orphan Drug, Rare Pediatric Disease, PRIME, ILAP, and Breakthrough Therapy for both indications, highlighting its potential in areas with significant unmet medical needs. The company also maintains an Expanded Access Program, which has shown ersodetug to be well-tolerated and effective in 13 tumor HI and 5 congenital HI patients, leading to substantial improvements in hypoglycemia and reduced IV glucose requirements.

Why It Matters

Rezolute's progress with ersodetug could significantly impact patients suffering from congenital and tumor hyperinsulinism, conditions currently lacking adequate FDA-approved treatments. Successful clinical trials and subsequent approval would offer new hope for individuals, particularly children, facing severe and life-threatening hypoglycemia, potentially reducing brain injury and improving quality of life. For investors, positive topline results from the sunRIZE study in December 2025 and the upLIFT study in late 2026 represent critical catalysts that could drive substantial share price appreciation. In a competitive landscape where current standard of care treatments are often suboptimal, ersodetug's unique mechanism of action and Breakthrough Therapy Designations position RZLT as a potential leader in this niche rare disease market.

Risk Assessment

Risk Level: high — The company's success is almost entirely dependent on the successful clinical development and regulatory approval of its single lead asset, ersodetug. Topline results for the sunRIZE Phase 3 study are anticipated in December 2025, and for the upLIFT Phase 3 study in the second half of 2026. Failure in either of these pivotal trials, or delays in regulatory approval, would severely impact the company's valuation and future prospects, as there are no other revenue-generating products.

Analyst Insight

Investors should closely monitor the anticipated December 2025 topline results for the sunRIZE Phase 3 study. Given the high-risk, high-reward profile, consider a speculative position if you have a high tolerance for risk, but be prepared for significant volatility around the data release.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

N/A

eps

N/A

gross Margin

N/A

cash Position

$258,827,000

revenue Growth

+0%

Key Numbers

• $258,827,000 — Aggregate market value of voting stock held by non-affiliates (as of December 31, 2024, based on a $4.90 share price)
• 90,811,368 — Shares of common stock outstanding (as of September 15, 2025)
• 56 — Participants in sunRIZE Phase 3 study (enrollment target exceeded for congenital HI)
• 16 — Participants in upLIFT Phase 3 study (minimum for truncated single-arm study for tumor HI)
• 1,500 — Estimated addressable market for congenital HI (individuals in the U.S. alone)
• 1,500 — Estimated addressable market for tumor HI (patients in the U.S. alone)
• 15 — Average hypoglycemia events per week (observed in sunRIZE study participants at baseline)
• 19% — Daily time spent in hypoglycemia (observed in sunRIZE study participants at baseline)
• 3.4 years — Average age of sunRIZE study participants (with 35% under age 2)
• 20 years — General patent effectiveness period (from earliest application filing date)

Key Players & Entities

• Rezolute, Inc. (company) — registrant
• ersodetug (company) — lead clinical asset
• FDA (regulator) — regulatory body
• EMA (regulator) — European Medicines Agency
• Nasdaq Capital Market (company) — stock exchange
• sunRIZE (company) — Phase 3 clinical study
• upLIFT (company) — Phase 3 registrational study
• Private Securities Litigation Reform Act of 1995 (regulator) — legal framework
• Sarbanes-Oxley Act (regulator) — legal framework
• Division of Diabetes, Lipid Disorders, and Obesity (regulator) — FDA office

FAQ

Risk Factors

• Delays in obtaining regulatory approval [high — regulatory]: Rezolute faces significant risks related to the timely receipt of regulatory approvals for ersodetug. The company's ability to commercialize its lead asset is contingent upon successful completion of ongoing Phase 3 trials (sunRIZE and upLIFT) and subsequent FDA review. Delays in these processes, or failure to obtain approval, could materially impact the company's financial condition and future prospects.
• Limited addressable market and competition [medium — market]: The addressable market for congenital and tumor hyperinsulinism is estimated at 1,500 patients in the U.S. for each indication. While these are rare diseases with significant unmet needs, the small patient populations may limit commercial potential. Rezolute must also contend with potential competition from existing or emerging therapies, although the company highlights ersodetug's unique mechanism of action and multiple designations.
• Reliance on clinical trial success [high — operational]: Rezolute's future hinges on the successful outcomes of its Phase 3 trials. The sunRIZE study for congenital HI is expected to report topline results in December 2025, and the upLIFT study for tumor HI in the second half of 2026. Any adverse results or unexpected safety concerns in these trials could severely impact the company's development timeline and valuation.
• Need for substantial future funding [high — financial]: As a late-stage biotechnology company, Rezolute will likely require significant capital to fund ongoing clinical trials, potential commercialization activities, and general operations. The company's ability to secure this funding through equity offerings, debt financing, or strategic partnerships will be critical to its continued existence and growth.
• Orphan drug exclusivity and market access [medium — regulatory]: While ersodetug has received Orphan Drug designation, which provides market exclusivity for a period, the company must navigate the complexities of market access and reimbursement in different geographies. Successful commercialization will depend on demonstrating clear value to payers and healthcare providers.
• Manufacturing and supply chain complexities [medium — operational]: Scaling up manufacturing for a novel biologic like ersodetug presents operational challenges. Ensuring a consistent, high-quality supply chain to meet potential market demand, especially for a rare disease therapy, will be crucial for successful commercialization.

Industry Context

Rezolute operates in the rare disease biotechnology sector, a field characterized by high unmet medical needs and significant scientific innovation. The company's focus on hyperinsulinism addresses a critical gap in treatment options for patients suffering from this ultra-rare condition. The industry is highly competitive, with companies investing heavily in R&D to develop novel therapies, often leveraging advanced biologics like monoclonal antibodies. Regulatory pathways for rare diseases, including orphan drug designations and expedited review programs, are crucial for bringing these therapies to market.

Regulatory Implications

Rezolute's development of ersodetug is subject to stringent regulatory oversight by agencies like the FDA. The company's success hinges on demonstrating the safety and efficacy of ersodetug through its ongoing Phase 3 trials (sunRIZE and upLIFT). Obtaining designations such as Orphan Drug and Breakthrough Therapy is positive, but does not guarantee approval. Rezolute must navigate complex regulatory requirements for clinical trials, manufacturing, and marketing authorization, with potential delays or rejections posing significant risks.

What Investors Should Do

1. Monitor December 2025 topline results for the sunRIZE Phase 3 study.
2. Track progress and enrollment in the upLIFT Phase 3 study for tumor HI.
3. Evaluate the company's cash burn and future financing needs.
4. Assess the competitive landscape and potential market penetration for ersodetug.

Key Dates

• 2025-05-01: Completed enrollment in sunRIZE Phase 3 study — Marks a critical milestone for the pivotal trial of ersodetug in congenital HI, moving closer to topline data.
• 2025-07-14: Presented preliminary patient demographics from sunRIZE study at ENDO — Provided early insights into the study population, potentially validating the trial design and patient characteristics.
• 2025-05-01: Initiated upLIFT Phase 3 study — Commenced the pivotal trial for ersodetug in tumor HI, with a modified, truncated single-arm design.
• 2025-12-01: Anticipated topline results from sunRIZE Phase 3 study — Key data readout that will determine the efficacy and safety of ersodetug for congenital HI, crucial for regulatory submission.
• 2026-12-31: Anticipated topline results from upLIFT Phase 3 study — Key data readout for ersodetug in tumor HI, essential for potential regulatory approval in this indication.

Glossary

Hyperinsulinism (HI)

A rare condition characterized by excessive production of insulin by the pancreas, leading to dangerously low blood sugar levels (hypoglycemia). (This is the primary disease area Rezolute is targeting with its lead asset, ersodetug.)

Ersodetug

Rezolute's lead investigational drug, a human monoclonal antibody designed to treat hypoglycemia caused by hyperinsulinism by down-modulating insulin receptor signaling. (The company's primary focus and potential revenue driver.)

Congenital Hyperinsulinism (CHI)

An ultra-rare pediatric genetic disorder where the pancreas overproduces insulin, causing severe hypoglycemia from birth. (One of the two main indications for ersodetug, with a pivotal Phase 3 study (sunRIZE) underway.)

Tumor Hyperinsulinism

A form of hyperinsulinism caused by insulin-producing tumors (insulinomas), leading to hypoglycemia. (The second indication for ersodetug, with a Phase 3 study (upLIFT) initiated.)

Monoclonal Antibody

A type of protein produced in a lab that can bind to specific targets, in this case, the insulin receptor. (Describes the nature of ersodetug and its mechanism of action.)

Hypoglycemia

A condition characterized by abnormally low blood glucose (sugar) levels, often causing symptoms like dizziness, confusion, and in severe cases, seizures or coma. (The core symptom that ersodetug aims to treat.)

Orphan Drug Designation

A status granted by regulatory agencies (like the FDA) to drugs intended to treat rare diseases, offering incentives such as market exclusivity and tax credits. (Ersodetug has received this designation for both indications, highlighting its potential for market protection.)

Breakthrough Therapy Designation

A designation granted by the FDA for drugs that demonstrate substantial improvement over available therapies for serious or life-threatening diseases. (Indicates strong potential for ersodetug and may expedite the development and review process.)

Year-Over-Year Comparison

Information comparing key metrics to the previous year, such as revenue, net income, and debt levels, is not available from the provided text. As a late-stage development company, Rezolute likely has minimal to no revenue and is focused on R&D expenditures, leading to net losses. The company's cash position is a critical metric, and its growth or decline would be a key indicator of its operational spending and financing activities compared to the prior period.

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 RZLT Nasdaq Capital Market Securi
• $4.90 — sed on the last reported sales price of $4.90 as quoted on the Nasdaq Capital Market
• $61.5 million — Development We incurred approximately $61.5 million and $55.7 million in research and devel
• $55.7 million — ncurred approximately $61.5 million and $55.7 million in research and development expenses fo

Filing Documents

• rzlt-20250630x10k.htm (10-K) — 2066KB
• rzlt-20250630xex4d1.htm (EX-4.1) — 67KB
• rzlt-20250630xex10d35.htm (EX-10.35) — 127KB
• rzlt-20250630xex19d1.htm (EX-19.1) — 228KB
• rzlt-20250630xex21d1.htm (EX-21.1) — 8KB
• rzlt-20250630xex23d1.htm (EX-23.1) — 3KB
• rzlt-20250630xex31d1.htm (EX-31.1) — 18KB
• rzlt-20250630xex32d1.htm (EX-32.1) — 9KB
• rzlt-20250630xex19d1001.jpg (GRAPHIC) — 2KB
• rzlt-20250630xex19d1009.jpg (GRAPHIC) — 2KB
• rzlt-20250630xex19d1010.jpg (GRAPHIC) — 2KB
• rzlt-20250630xex19d1011.jpg (GRAPHIC) — 2KB
• rzlt-20250630xex19d1012.jpg (GRAPHIC) — 1KB
• rzlt-20250630xex19d1014.jpg (GRAPHIC) — 2KB
• 0001104659-25-090848.txt ( ) — 10817KB
• rzlt-20250630.xsd (EX-101.SCH) — 77KB
• rzlt-20250630_cal.xml (EX-101.CAL) — 51KB
• rzlt-20250630_def.xml (EX-101.DEF) — 371KB
• rzlt-20250630_lab.xml (EX-101.LAB) — 635KB
• rzlt-20250630_pre.xml (EX-101.PRE) — 549KB
• rzlt-20250630x10k_htm.xml (XML) — 1871KB

Business

Item 1. Business 1

Risk Factors

Item 1A. Risk Factors 6

Unresolved Staff Comments

Item 1B. Unresolved Staff Comments 17

Cybersecurity

Item 1C. Cybersecurity 17

Properties

Item 2. Properties 18

Legal Proceedings

Item 3. Legal Proceedings 18

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 18 Part II

Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 18

[Reserved]

Item 6. [Reserved] 19

Management's Discussion and Analysis of Financial Condition and Result of Operations

Item 7. Management's Discussion and Analysis of Financial Condition and Result of Operations 19

Quantitative and Qualitative Disclosures About Market Risk

Item 7A. Quantitative and Qualitative Disclosures About Market Risk 27

Financial Statements and Supplementary Data

Item 8. Financial Statements and Supplementary Data 28

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 60

Controls and Procedures

Item 9A. Controls and Procedures 60

Other Information

Item 9B. Other Information 61

Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 61 Part III

Directors, Executive Officers and Corporate Governance

Item 10. Directors, Executive Officers and Corporate Governance 62

Executive Compensation

Item 11. Executive Compensation 62

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 62

Certain Relationships and Related Transactions, and Director Independence

Item 13. Certain Relationships and Related Transactions, and Director Independence 62

Principal Accounting Fees and Services

Item 14. Principal Accounting Fees and Services 62 Part IV

Exhibits and Financial Statement Schedules

Item 15. Exhibits and Financial Statement Schedules 62

Form 10-K Summary

Item 16. Form 10-K Summary 65

Signatures

Signatures 66 -i- - Table of Contents CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K for the fiscal year ended June 30, 2025 ("Annual Report") contains statements reflecting assumptions, expectations, projections, intentions or beliefs about future events that are intended as "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements included or incorporated by reference in this Annual Report, other than statements of historical fact, that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. These statements appear in a number of places, including, but not limited to " Management's Discussion and Analysis of Financial Condition and Results of Operations." These statements represent our reasonable judgment of the future based on various factors and using numerous assumptions and are subject to known and unknown risks, uncertainties and other factors that could cause our actual results and financial position to differ materially from those contemplated by the statements. You can identify these statements by the fact that they do not relate strictly to historical or current facts, and use words such as "anticipate," "believe," "estimate," "expect," "forecast," "may," "should," "plan," "project" and other words of similar meaning. In particular, these include, but are not limited to, statements relating to the following: our ability to obtain regulatory approvals for our therapeutics in development; our expectations regarding clinical development and the timeline to complete clinical studies; our projected operating or financial results, including anticipated cash flows to be used in operating activities; our expectations regarding capital expenditures, research and development ("R&D") expenses and the timing of milestone payments required under license agreements

Business

Item 1. Business. Rezolute, Inc. ("Rezolute", the "Company", "we" or "us") is a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism ("HI"). Summary of Clinical Assets Ersodetug Our lead clinical asset, ersodetug, is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism. Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. The antibody down modulates insulin's binding, signaling, and action thereby counteracting the effects of elevated insulin in the body, and helping to restore glucose to a more normalized range. Ersodetug shows dose dependent pharmacokinetics with a half-life greater than 2 weeks, which has the potential for monthly dosing. Therefore, we believe that ersodetug is ideally suited as a potential therapy for conditions characterized by excessive insulin or insulin-like levels, and it is being developed to treat hyperinsulinism. As ersodetug acts downstream from beta cells, it has the potential to be universally effective at treating hypoglycemia related to HI, whether genetic or acquired. Ersodetug for Congenital Hyperinsulinism sunRIZE Phase 3 Study We completed enrollment in May 2025 of a pivotal Phase 3 clinical study (the "sunRIZE" study) of ersodetug for the treatment of hypoglycemia in participants with congenital HI, an ultra-rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas. The study was to enroll approximately 56 participants in more than a dozen countries around the world, inclusive of U.S. patients, and enrollment target was exceeded. Topline results from the study are anticipated to be available in December 2025, but the specific date of the availability of such results may vary. The sunRIZE study is a global, randomized, doub

View Full Filing

View this 10-K filing on SEC EDGAR